Home โบ Mesothelioma
Mesothelioma clinical trials recruiting in the U.S.
45 studies for Mesothelioma are recruiting participants at sites across the United States.
Mesothelioma is a tumor of mesothelium, a tissue that lines lungs and other organs. Most people who get it have inhaled asbestos. Read the symptoms.
Cities with the most studies
- Houston, TX15 studies
- New York City, NY10 studies
- Washington, DC9 studies
- Chicago, IL9 studies
- Nashville, TN8 studies
- Boston, MA8 studies
- Arlington, VA6 studies
- Philadelphia, PA6 studies
- Pittsburgh, PA6 studies
- Seattle, WA6 studies
- Los Angeles, CA6 studies
- Rochester, MN5 studies
- Columbus, OH5 studies
- Edison, NJ5 studies
- San Antonio, TX4 studies
- San Diego, CA4 studies
- St. Louis, MO4 studies
- Tampa, FL4 studies
- Jacksonville, FL4 studies
- Phoenix, AZ4 studies
- Queens, NY4 studies
- Dallas, TX4 studies
- Omaha, NE4 studies
- Grand Rapids, MI3 studies
- Denver, CO3 studies
- Detroit, MI3 studies
- Santa Monica, CA3 studies
- Mountain View, CA3 studies
- New Rochelle, NY3 studies
- East Norwalk, CT3 studies
- Staten Island, NY3 studies
- Greenburgh, NY3 studies
- Miami, FL3 studies
- Santa Rosa, CA3 studies
- Fort Worth, TX3 studies
- Durham, NC3 studies
By state
- Arizona7 studies
- California12 studies
- Colorado8 studies
- Florida12 studies
- Georgia3 studies
- Illinois11 studies
- Kansas3 studies
- Maryland10 studies
- Massachusetts10 studies
- Michigan6 studies
- Minnesota8 studies
- Missouri5 studies
- Nebraska4 studies
- New Jersey8 studies
- New York11 studies
- North Carolina4 studies
- Ohio9 studies
- Pennsylvania13 studies
- Tennessee8 studies
- Texas19 studies
- Utah4 studies
- Virginia8 studies
- Washington6 studies
- Wisconsin3 studies
Recently updated studies
SW-682 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT06251310Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
RecruitingObservational study
Ages 2 to 120 ยท All sexes ยท Updated Oct 2, 2026 ยท NCT00242723Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RecruitingObservational study
Ages 2 to 100 ยท All sexes ยท Updated Oct 2, 2026 ยท NCT01950572Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RecruitingPhase 1
Ages 18 to 120 ยท All sexes ยท Updated Oct 2, 2026 ยท NCT06885697Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
RecruitingObservational study
Ages 2 to 120 ยท All sexes ยท Updated Oct 2, 2026 ยท NCT03830229Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT05932199Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
RecruitingObservational studyHealthy volunteers welcome
Ages 30 to 120 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT04431024A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07277413Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT04981119Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Recruiting
Ages 30 to 85 ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06037941A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06057935Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
RecruitingPhase 2
Ages 18 to 120 ยท All sexes ยท Updated Sep 23, 2026 ยท NCT05960773A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 18, 2026 ยท NCT07705334Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 16, 2026 ยท NCT06566079TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 15, 2026 ยท NCT04969315Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 8, 2026 ยท NCT05732831Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 2, 2026 ยท NCT05245500A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Aug 19, 2026 ยท NCT04104776Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
RecruitingPhase 1
Ages 18 to 79 ยท All sexes ยท Updated Aug 4, 2026 ยท NCT07192900Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Aug 4, 2026 ยท NCT05579366Lead-212 PSV359 Therapy for Patients With Solid Tumors
RecruitingPhase 1/2
Ages 18 to 90 ยท All sexes ยท Updated Jul 6, 2026 ยท NCT06710756Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 ยท All sexes ยท Updated Jun 29, 2026 ยท NCT02012699SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Jun 24, 2026 ยท NCT05568680CT-95 in Advanced Cancers Associated With Mesothelin Expression
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Jun 12, 2026 ยท NCT06756035A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Jun 12, 2026 ยท NCT06051695From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.